» Articles » PMID: 29334232

Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: Imaging Evaluation Post Treatment

Overview
Journal Br J Radiol
Specialty Radiology
Date 2018 Jan 16
PMID 29334232
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Surgical resection, when feasible, is the standard of care for hepatocellular carcinoma. However, many tumours are not resectable at the time of diagnosis. Recently, stereotactic body radiation therapy (SBRT) has emerged as a non-invasive local therapy for both non-resectable primary hepatic malignancies as well as hepatic metastases. Knowledge of the expected hepatic parenchymal appearance post treatment, as well as potential pitfalls and complications, is essential for accurate evaluation of treatment response. This pictorial review provides a fundamental description of the SBRT technique, outlines the expected cross-sectional imaging appearances of tumour response, and highlights potential pitfalls in interpretation. The expected liver parenchymal changes post-SBRT are also reviewed, along with some common radiation-induced complications.

Citing Articles

The Negative Impact of Sarcopenia on Hepatocellular Carcinoma Treatment Outcomes.

Cespiati A, Smith D, Lombardi R, Fracanzani A Cancers (Basel). 2024; 16(13).

PMID: 39001378 PMC: 11240545. DOI: 10.3390/cancers16132315.


Liver stereotactic body radiation therapy without fiducial or retained ethiodized oil guidance warrants greater than 5 mm planning target volumes.

Breazeale A, Rahmani R, Gallagher K, Nabavizadeh N J Med Radiat Sci. 2023; 71(1):110-113.

PMID: 37712320 PMC: 10920930. DOI: 10.1002/jmrs.726.


Role of Functional MRI in Liver SBRT: Current Use and Future Directions.

Tadimalla S, Wang W, Haworth A Cancers (Basel). 2022; 14(23).

PMID: 36497342 PMC: 9739660. DOI: 10.3390/cancers14235860.


Characterization and Prediction of Signal Intensity Changes in Normal Liver Parenchyma on Gadoxetic Acid-enhanced MRI Scans after Liver-directed Radiation Therapy.

Nehlsen A, Sindhu K, Wolken T, Khan F, Kyriakakos C, Ward S Radiol Imaging Cancer. 2022; 4(4):e210100.

PMID: 35904411 PMC: 9358658. DOI: 10.1148/rycan.210100.


The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy.

Xu Y, Yang Y, Li L, Ye F, Zhao X Front Oncol. 2022; 12:905260.

PMID: 35686094 PMC: 9170883. DOI: 10.3389/fonc.2022.905260.


References
1.
Khan M, Combs C, Brunt E, Lowe V, Wolverson M, Solomon H . Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000; 32(5):792-7. DOI: 10.1016/s0168-8278(00)80248-2. View

2.
Park M, Kim S, Yoon S, Kim J, Park S, Lee S . Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed tomography. PLoS One. 2014; 9(2):e90327. PMC: 3938667. DOI: 10.1371/journal.pone.0090327. View

3.
Sawyer B, Pun E, Samuel M, Tay H, Kron T, Bressel M . CT perfusion imaging in response assessment of pulmonary metastases undergoing stereotactic ablative radiotherapy. J Med Imaging Radiat Oncol. 2015; 59(2):207-15. DOI: 10.1111/1754-9485.12272. View

4.
Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

5.
Brook O, Thornton E, Mendiratta-Lala M, Mahadevan A, Raptopoulos V, Brook A . CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors. Gastroenterol Res Pract. 2015; 2015:126245. PMC: 4499630. DOI: 10.1155/2015/126245. View